Immunovant’s latest earnings call projected clear optimism, as management leaned into robust Phase II data for brepocitinib in cutaneous sarcoidosis and a deep pipeline of registrational trials.

View Immunovant Inc IMVT stock quote prices, financial information, real-time forecasts, and company news from CNN.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated ...

A month has gone by since the last earnings report for Immunovant, Inc. (IMVT). Shares have lost about 1.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Immunovant (IMVT) just made waves by announcing it will present new six-month, off-treatment data from its proof-of-concept study of batoclimab in Graves' disease at the upcoming American Thyroid ...

A month has gone by since the last earnings report for Immunovant, Inc. (IMVT). Shares have added about 3.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Immunovant develops monoclonal antibody therapeutics targeting autoimmune diseases. The firm operates a clinical-stage biopharmaceutical model, generating value through the advancement of proprietary ...

Immunovant focuses on autoimmune disorders. The company said on Tuesday, before the markets opened, that IMVT-1402, in a phase 1 trial, using subcutaneous doses, achieved peak immunoglobulin G (IgG) ...

One stock that might be an intriguing choice for investors right now is Immunovant, Inc. IMVT. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other ...